Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
Dermacyd PH_DETINBACK Sweet Flower · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd PH\_DETINBACK (Lactic Acid) Sweet Flower |
| Name | Type | Description |
|---|---|---|
| Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower | DRUG | - |
Inclusion criteria: * Integral skin test in the region; * Use of cosmetic product of the same category; * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time; Exclusion criteria: * Lactation or gestational risk or gestation; * Use of Anti-i...
Dermacyd PH_DETINBACK Sweet Flower is a small molecule product developed by Sanofi for hygiene use. It is also known as Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower. The product has been studied in a Phase 3 trial in Brazil involving 31 female participants aged 10 years and older.
Dermacyd PH_DETINBACK Sweet Flower is intended for hygiene purposes. Its specific indications are not publicly disclosed. The product has been evaluated in a Phase 3 safety study in Brazil with 31 healthy female volunteers aged 10 years and older.
Dermacyd PH_DETINBACK Sweet Flower is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of this small molecule product, which has completed a Phase 3 trial in Brazil.
Dermacyd PH_DETINBACK Sweet Flower has completed a Phase 3 clinical trial. It is an investigational product and is not approved by the FDA. The trial, NCT00785850, was a Phase 3 safety study conducted in Brazil with 31 participants.
Dermacyd PH_DETINBACK Sweet Flower has been studied in one completed Phase 3 trial, NCT00785850, titled "Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety." The trial enrolled 31 healthy female volunteers aged 10 years and older in Brazil and focused on hygiene.
Yes, Dermacyd PH_DETINBACK Sweet Flower is also known as Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower. Both names refer to the same Sanofi product, which has completed a Phase 3 safety trial in Brazil.